Liposomal amphotericin B: an effective, nontoxic preparation for the treatment of urinary tract infections caused by Candida albicans.
Liposomal amphotericin B without prior administration of Fungizone was found to be an effective treatment in 4 patients with urinary tract infections caused by Candida albicans. Urine typically became culture negative after 1-4 days of dosing at 50 mg/day, demonstrating that therapeutic levels of amphotericin B were reached in the urine at conventional doses given in liposomal form. The low incidence of toxicity with this preparation was particularly useful in patients with impaired renal function, including renal transplant patients on cyclosporine immunosuppression.
Ralph
E D
ED
Department of Medicine, University of Western Ontario, London, Canada.
Barber
K R
KR
Grant
C W
CW
D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy*; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology*
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B